Related Experiment Video

Updated: Jun 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

[New hypoglycemic agents in type 2 diabetes]

Bruno Guerci1, Charles Halter

  • 1Université de Nancy I et service de diabétologie, maladies métaboliques et maladies de la nutrition, hôpital Jeanne-d'Arc, CHU de Nancy, 54201 Toul BP 90303. b.guerci@chu-nancy.fr

La Revue Du Praticien
|May 15, 2010
PubMed

Insights

New type 2 diabetes treatments leverage incretins like GLP-1. Therapies include GLP-1 receptor agonists and DPP-4 inhibitors, offering improved glucose control and potential weight loss, though long-term safety requires further study.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes involves altered incretin effect, with reduced glucagon-like peptide-1 (GLP-1) concentrations.
  • GLP-1 plays a crucial role in glucose homeostasis, with glucose-dependent insulin secretion and glucagon regulation.
  • Existing incretin-based therapies aim to restore the diminished incretin effect in type 2 diabetes patients.

Purpose of the Study:

  • To review novel therapeutic strategies for type 2 diabetes targeting the incretin system.
  • To compare the efficacy and side effect profiles of GLP-1 receptor agonists and DPP-4 inhibitors.
  • To assess the impact of these treatments on glycemic control, weight, and overall patient tolerance.

Main Methods:

  • Review of current literature on incretin-based therapies for type 2 diabetes.
  • Comparative analysis of subcutaneous GLP-1 receptor agonists and oral DPP-4 inhibitors.
  • Evaluation of reported HbA1c reductions, weight changes, and adverse events.

Main Results:

  • GLP-1 receptor agonists showed HbA1c reductions of 0.8-1.5% and significant weight loss (1.6-3.8 kg) due to reduced gastric emptying and satiety control.
  • DPP-4 inhibitors demonstrated HbA1c reductions of 0.5-1.1% with generally good tolerance.
  • GLP-1 receptor agonists were associated with gastrointestinal side effects like nausea and vomiting, particularly upon initiation.

Conclusions:

  • Both GLP-1 receptor agonists and DPP-4 inhibitors represent effective strategies for managing type 2 diabetes by enhancing the incretin system.
  • GLP-1 receptor agonists offer additional benefits of weight loss, while DPP-4 inhibitors provide oral administration convenience and better initial tolerance.
  • Further research is necessary to fully establish the long-term effectiveness and safety profiles of these innovative incretin-based treatments.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...